DelveInsight’s ‘Acute Respiratory Distress Syndrome-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Acute Respiratory Distress Syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 7MM Acute Respiratory Distress Syndrome market size from 2019 to 2032. The Report also covers current Acute Respiratory Distress Syndrome treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Acute Respiratory Distress Syndrome Market Report:
Key Benefits of the Report:
Got queries? Click here to know more about the Acute Respiratory Distress Syndrome Market Landscape.
Acute respiratory distress syndrome (ARDS) Overview
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.
Out of total COVID-19 cases, the patients who are critically ill—very few and ranging from 1–4%—constitute the potential pool for ARDS. The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The few symptoms of ARDS are shortness of breath, cough, and fever; in some cases, fast heart rates and rapid breathing have been reported as well. Occasionally, patients of ARDS experience chest pain, especially during inhalation, and some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. Several risk factors may escalate the risk of ARDS; this involves obesity, alcohol abuse, chemotherapy, and low-protein in blood.
Acute respiratory distress syndrome (ARDS) Epidemiology Segmentation
Acute respiratory distress syndrome (ARDS) Market
The therapeutic market of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets was USD 1,065.7 Million in the year 2021. The United States accounts for the highest market size of Acute Respiratory Distress Syndrome (ARDS), in comparison to the other seven major markets, i.e., EU5 countries and Japan. Among the EU5 countries, Germany contributed the largest market share in EU5 countries, with approximately 62.47%, followed by France (14.74%) in the year 2021.
Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. Other treatment options, which the patients with ARDS are generally subjected to include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.
Learn more by requesting for sample @ Acute Respiratory Distress Syndrome Market Landscape
Acute Respiratory Distress Syndrome Market Drivers
Acute Respiratory Distress Syndrome Market Barriers
Acute Respiratory Distress Syndrome Key Companies
Acute Respiratory Distress SyndromeTherapies
Table of Contents
Click here to read more about Acute Respiratory Distress Syndrome Market Outlook 2032
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/